Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I care tj, and so does every Good Guy (and Gal) watching BIEL and the progress of the ClassII initiative by the FDA on the web and here on iHub.
I cannot argue with your speculation on timelines, either pro or con, but my sense is the new ClassII designation will be rather soon, given that a couple of months have passed since public comments closed May 21, 2014. Am I able to define 'rather soon’? Not any better than any one else, but I like your shot at it.
If we twist and pull at the English language, it sets up something like this and this is totally off the cuff:
1 is 1 and cannot be anything else;
2 is a couple and cannot be 1, or a few, so it is less than a few;
3 or more is a few;
Many is more than a few, making the difference between a few and many very murky, so we need a tighter definition;
Tucked in there somewhere is the delicious word 'several';
Now, several is defined, I think, as more than 2, but fewer than many. On the other hand, several in law is defined as 2 or more.
Not much less murky, I'm afraid, but I am comfortable going with 'several' and I sense that several in this case is more than 2, which is where we are essentially from May 21st, and less than 5, meaning between 3 or 4, but less than 5, which would be somewhere between August 21st and October 21st! All of which is why the best word, the one I use for everyone who asks me for a definitive time for something to happen, is soon. I'm not a very good philologist, but soon is a wonderful word; you can't be trapped by it, you can repeat it anytime in the future and you will always be right, no matter how long it takes for the something to happen! Having used soon as the best descriptive word I can think of, do I hope it will be 'sooner' than October 21st? Yes.
To assuage your irritation at me, have you read the comments of the coalition of 4 separate device companies to the FDA recently? It's very well done, makes very interesting reading, and I think you will see that, combined with the verbiage in the Proposed Order published by the FDA, this train has left the station and is gathering momentum toward the creation of a new ClassII designation for these devices, soon.
http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/medicaldevices/medicaldevicesadvisorycommittee/orthopaedicandrehabilitationdevicespanel/ucm359207.pdf
With the greatest of respect, this is not the game of darts. Should read everything available then form your opinion - saves time and more accurate.
May of 13 was the start of serious forward momentum at the FDA, May of 14 was when public comments closed. FDA assessed those mostly positive comments and are now working to final steps. This issue is but one of thousands on the FDA workbench, but I am confident they now 'get it' that PEMF, SWT is a solution to the drug candy culture we have created in America and that by creating a new ClassII designation for BIEL's and similar devices, in the FDA's own words, "on its own initiative", and "based on new information", with certain restrictions, labels, printed data and warning, like don't swallow the ActiPatch if you have stomach pain, will go a long way toward resolving the crisis urgent need for drug-free, side-effect free pain management in our country. Judging by the usual 'follow America' trends in such things, these actions will have a positive influence on the world. Sales trends in many developed countries follow the lead of the FDA and sales trends here.
Just an added thought on my last post. Seems to me that if the large pharmaceutical companies knew of the specific information spewing out of the mouths of some of the registered lobbyists in DC, there might just be less lobbyists. Lobbyists are paid messengers, compensated to deliver information to decision makers and their staffs and gain support and ultimately votes. Some play it straight and truthfully, but there is an element that if the lobbyist is not successful, lobbyist gets canned, therefor manipulation and rhetoric are elevated until success is achieved.
Theory, I represent a large pharma firm client, if I do a great job, I can increase my income. Is this not temptation?
You're welcome 7up. As I said at the beginning, pure speculation, but the cool thing is that I base it on the factual developments to date, rather than others who opine negatively based on non-business needs. One is no more accurate, or inaccurate, until the story unfolds and I am confident the FDA will issue its Proposed Order for a ClassII device designation in final Order form and BIEL will move forward through the 510(K) application process for OTC sales approval.
The end result of course is that if/when BIEL succeeds then the persistent naysayers will look foolish, the American people will have drug-free, side-effect free pain management choices for the first time in our history and the Good Guys and BIEL shareholders will have made some money; if, on the other hand, BIEL fails then the naysayers will gloat, the American people will continue their pain drug dependency by consuming 80% of the global chemical Rx and OTC painkillers and the Good Guys and BIEL shareholders will have lost some money.
I like the odds of the FDA continuing on its self declared "own initiative" in its Proposed Order to help the American people to have safe, efficacious alternatives to the drugs doctors are prescribing and we are both asking for and taking like candy. Anyone opposed to positive change in our habits with respect to prescription and OTC painkillers seems un-American to me and should be both silent and ashamed of themselves. The drug crisis is bigger than all of us, killing many thousands of people every year and we must promote remedies. I salute the FDA management and staff and the folks we have sent to Washington and their obvious courage to do the right thing, in spite of the powerful pharmaceutical industry and financial clout and lobbyists, etc.
OK, thanks Jonas.
Pure speculation from a little spreadsheet I did:
Numerous assumptions of course, I'll be brief. Held back a few secrets
* Assume JV AND LA, rather than straight LA
*Assume ramp-up over 3 year period
Assume JV partner has existing field force of 500 plus in pain management and manufacturing/assembly facility and capacity
* Assume 7 Billion shares
* Assume I included nothing for RecoveryRx.
* Used product list from BIEL website.
* No consideration of specific applications like knee, ankle, shoulder. ActiPatch is general use
* Used U.S. only @ 300Million population ,excluding too young and too elderly
* Assume no consideration for chronic users
* used market penetration of ActiPatch 5%, Smart Insole 1%, Allay 3%, HealFast 1% and product volume in units per user of 4, 4, 3 and 3
* Used margin of 80%
Numbers crunch as follows, use your own multiple to determine share price.
Valuation of BIEL
Up-front, Milestone Payments, Annual Royalties, Term, Renewals
Products – ActiPatch, Smart Insole, Allay, HealFast
Selling Price of all - $34.99
Hours – 720
Cost / hour – 5 cents
Sales volume units (million) 60; 12; 27; 4.5 – Total 103.5 million units
$$ Sales (billion) – Total $3.621465
$$ Margin (billion) @ 80% - $2.897172
Multiple – 6 $2.48
Multiple – 10 $4.14
Multiple – 20 $8.28
Multiple – 50 $20.69
Have at it.
OK, I guess I won't comment on jimzin's question in 41161 on valuation of BIEL
May I comment / speculate?
It's your decision and only your decision tj - only advice I can offer up for you to consider is that the positive posts seem generally backed by factual developments such as with the FDA admitting it needed to do work internally to increase its knowledge of PEMF science; moving to create a new ClassII designation to hold BIEL products, and those of others; no side-effects; no drugs; high efficacy; ongoing trials; new products; and positive reception by Boots' customers in the UK, among numerous other positive signs.
Conversely, it seems to me that every negative post here that doesn't reference the past mistakes of BIEL management spews forth much mean-spirited and vengeful rhetoric that is consistently unencumbered with the truth. Only negatives I buy into are the passage of valuable time on the primary patent, which would have been shored up by BIEL's patent attorneys and the substantial increases in shares made necessary in order to finance the company for the past 5 years of its development, something I may well have done myself. I've also long suspected that some very substantial entity is a buyer of millions of shares as an agreed to means of financing BIEL's operating expense.
You decide
Hey mad, how are you? Any lingering anger by anyone toward Whelan, after years, is unproductive and might be better steered toward the positive, based on the efforts and results of many in developing the Boots relationship and improving the product design and trial database at BIEL, wouldn't you agree? Would you not also agree that the management team of BIEL has made progress in seeming to be working with the FDA, rather than antagonistically? Anger is a killer my friend and to date I don't believe BIEL has developed an AngerPatch, or an IrePatch, or a PiccedPatch for that matter. :)
Such review data is most always skewed Yankee, since it only reflects the review data submitted by users. In this case, the positive review data may be much higher if one includes satisfied users who did not respond to the request to submit a review. Somewhat nebulous, I know, but it could mean a 90%, or higher, positive experience by users. It would be interesting to actually read the responses that were not judged to be positive. Were they negative or neutral for example? Or because of pricing or affordability? At the end of the day, 80% is very significant and bodes well for repeat sales.
Just to help Arizzle - perhaps you might consider reading my posts
40979; 980; 983; and 992? Won't take but a few minutes and you'll be totally on top of this.
Oooops - I see now where you are - different space my friend - not in the new to-be-created ClassII space BIEL will slip into - all this was posted last week. Don't quit Arizzle - you've got a good nose for this
Hey Arizzle - you state the new class of devices has already been set up and 50(K) applications under that Class submitted your posts 41089 and 41097. Are you able to provide your link source of these facts?
Seems strange to me that there is no record in the Federal Register where the Order would be published, nor has there been a BIEL News Release to that effect, which astonishes me, if you are correct. Would you please humor me and my ignorance and provide the correct link? Thank you.
It may evolve Arizzle that there may be a very narrow window of time during which shares may be acquired.
If I'm running BIEL, my science experts, and others in my management team, have been working with FDA staff to determine the timing of the release of the final Order creating the new Class II home for BIEL's products. We do not know that FDA staff have not been in touch with BIEL and the companies forming the comment coalition simply to ask them questions about comments received prior to the May 21 cut-off.
Therefor, by working with the FDA, as opposed to against, as before, BIEL would be in a better position to be able to immediately file its 510K), as will others to be "in the game", as it were, of assessment and approval. That will commence the next 60 day time tranche for the FDA to review and decide on the safety and efficacy of BIEL's product(s). Make no mistake, the FDA knows now exactly what it's doing in the device space and therefor there must be a timeline describing every step of the process. It would be stupid to think there is not.
Any thoughts 7up on my timing thoughts posed in last paragraph of post 41059?
Love your punny humor bieliver (problems reduced with ActiPatch)
Thanks for the comparison cashpot - well thought out.
In other words, there is just no comparison between TENS and BIEL's products. Apples and Oranges. Perhaps Sanofi would like a total lock on non-chemical pain management devices. Hadn't thought of that. Too obvious, I guess. I frequently thought J&J would be a logical player given the potential loss in sales of Tylenol 1 through 4 when common sense prevails about chemical drugs and their side-effects.
I also think about it this way - did the FDA have a devices division 10 years ago? It's a process and BIEL is very close. I also wonder if the FDA is perhaps working to a schedule of 60 day timing tranches? 60 days to May 21 for public comments to its Proposed Order - 60 days to July 21, or so, for it to review those comments and edit the Proposed Order to Final Oder? Just wondering.
Absolutely right art - the big pharmaco would be screaming it loud and clear that it had discovered the second coming and sliced bread! Breakthrough approved in record time to save American lives! Nobel prize material, no doubt! Pharmaco's share price skyrockets on the NYSE from $18 to $125 in 6 trading session! I can hear it all now.
I understand what you are saying Arrizzle, but wouldn't you think the company could easily raise $1.8Million, less fees and commissions to Vndm, far more easily that by dilution selling at $ .0018? Makes no sense to me, compared to just completing a proper financing and the price jumps a bit just on that news, never mind the pending FDA reclassification news. I would appreciate your thoughts on possible options available to BIEL.
And very wise opinions they are shado - thank you for sharing them.
My sense is that Whelan is not going to be steamrolled by an acquirer, or an M&A house looking for a project, based on his long business experience and his Irish, ex-USMC stubbornness. On a more materialistic basis, there is the BIEL IP, the patents, along with all the trial data and so on.
Similar to my opinion that he will not entertain a reverse-split at this late juncture in the regulatory approval process with the FDA Proposed Order for creation of the Class II device classification fairly close at hand, it seems doubtful to me that he would be vulnerable to a steamroller.
Tks fuj - hope you're well
Ahhhhh, yankee, most assuredly, you shower me with undeserved accolades, you must have been researching among those you know at universities, since I prefer the quiet of professional anonymity.
I believe it is too strongly worded to label our governmental bureaucracies as fulfilling "enabler roles". Perhaps stuck in inertia may be more appropriate?
Seems to me that members in a staff function right up to directors have a legitimate fear of their elected masters and the combined effect of the media paying too much attention to the latest citizen in the limelight or their lawyer. Same applies to our elected officials, always working on being re-elected, who fear their financial benefactors and the same media, citizens and their lawyers for never doing enough. Ergo, inertia.
The PEMF/SWT BIEL debacle should be larger and more critical than all of the above fears and resulting inertia. However, the solution process needs a hero, or three, or more. At the moment, the FDA is the primary hero. It courageously conducted a self-analysis, highly critical of its internal lack of understanding of BIEL's device field in general. It then had the courage to say it loud and clear publicly with solutions that it was going o hire 25 or more pros to deal with the problem, which it did.
It then called a public meeting for folks to come forward and voice their issues. Then produced its Proposed Order to reclassify the devices into Class II, with the invitation to make comments electronically or by mail. It has reviewed those 400 or so, mostly positive, comments and is most probably editing the Proposed Order into its final form. Therefor, I say carefully that, on balance, all this seems to me to have taken place in a relatively short period of time.
Meanwhile, BIEL has tried to advance its cause globally on a shoestring budget, Doctor OZ put it on a program with positive results and the program in England with Boots is taking off. Any politician here in the US could have taken up the cause we all know about. Globally, over 95% of oxycodone and over 80% of drug painkillers are consumed here in the US. The JAMA June report talks about 100 Million American chronic pain sufferers costing us $600Billion, yet we have no heroes, no crusaders. Why? Inertia.
So, my friend yankee, where will the next hero come from to support BIEL, and others in the field, and the FDA in the now critical process of eradicating the abuse of chemical painkillers from our country to acceptable levels? I don't know, and what distresses me more is that no one knows, but with your help, lizanne's, people like 7up and jimzin, veto who has been posting since 08 or 09 and all the other Good Guys, heroes will emerge. They have to, it's our way to crisis-manage our country out of such debacles, just takes heroes.
Will it be a Sanjay Gupta? Perfect candidate who has spoken out about drugs - 45 years old - did you know he was offered the job of U.S. Surgeon General, at 40, and turned it down? Dr. Gupta has more credibility than any other individual in DC, hands down. Will it be Oprah? Don't know. The dream of all television producers, seems to me, would be a televised Town Hall meeting televised in prime time on the subject with a small number of participants from both sides of the aisle and Doctor Gupta in the middle.
For those participating and following through, by encouraging BIEL and others to stay the course and joining the FDA as heroes in 'gettin er done' quickly, campaign financing and re-election would be non-issues for many years. Starting to appear as if any dissenters, be they existing drug companies or others, to saving billions of dollars and many thousands of American lives by moving the process of drug-free, side-effect free pain management ahead quickly would simply be un-American. How's that for a label? Wouldn't surprise me one bit, as I've said for a long time, if J&J's device division got into this by joining forces with BIEL, particularly given that Alex Gorsky, current Chairman and CEO ran J&J's device division prior to his appointment at the top. Just my thoughts, sorry to be long-winded, but it's a subject that warrants imaginative courage to think outside the box, thus its length. I had no intention of making a speech, but I was asked for my opinion. . . . thank you for that, I'm honored.
Thanks very much Yankee. I've been saying things like, "destroying ourselves from within", etc., etc., etc.
This link you put up and the quotes articulate it as well. "Cultural transformation" says it well, but is it speedy enough to stop, or even slow down, the systemic internal deterioration of a chemical drug trend gone mad?
I'd say 100 million people suffering from chronic pain at an annual cost of $600 Billion needs higher octane, in the form of faster change from Washington, than, "cultural transformation". We need full acknowledgement of the present and looming disastrous issues and then strong professionals, and citizens, screaming from the rooftops, then brave leadership to say, "enough, we must move to create change now, not in 4 more do-nothing years, now! Over to you DC! We are killing ourselves internally with chemical drugs and companies like BIEL are in the wings with drug-free devices? ARe you kidding me? The bad guys don't have to do a thing, we're wiping ourselves out! Now tell me drug-free, side-effect free pain management devices, like BIEL's aren't timely and critical. The war against drugs isn't about idiots getting high on street drugs, or making pot legal so people can get stupid, the drug war is about doctors prescribing drugs and retailers selling chemicals for pain management. Boy, are we stupid!
Thanks for all 3 Stockin
Published this afternoon by FDA - kind of cool.
http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/PMAApprovals/ucm404223.htm
April 2014 PMA Approvals
In particular at the end:
Summary of PMA Originals & Supplements Approved
Originals: 1
Supplements: 93
Summary of PMA Originals Under Review
Total Under Review: 52
Total Active: 27
Total On Hold: 25
Summary of PMA Supplements Under Review
Total Under Review: 580
Total Active: 455
Total On Hold: 125
Summary of All PMA Submissions Received
Originals: 3
Supplements: 104
Summary of PMA Supplement PMA Approval/Denial Decision Times
Number of Approvals: 93
Number of Denials: 0
Average Days Fr Receipt to Decision (Total Time): 182.7
FDA Time: 134.8 Days MFR Time: 48.0 Days
Suggest you very carefully piece together the neurometrix historical data; financials, the 1 for 6 reverse split, the 2013 financing, the 2014 financing closed June 24, 2014 and see if you still come up with 6 Million shares. One thing I know for sure is, I don't know, but who am I?
Thanks for raising the subject 57, good food for thought. If your number of 6Million shares, given that they just blew out a couple million shares on a very small financing and given that a 52. Week high of over $4, management probably estimates the company is worth $100 a share - fine with me as that would make BIEL a dollar a share.
There are many variables that go into valuing shares, not just a mathematical multiples of outstanding shares, just saying. I like the difference in retail sticker price - many hundreds of dollars for a TENS devicwe versus BIEL's 30 bucks for the ActiPatch, which is not a TENS device - apples and oranges. Perhaps all this makes BIEL worth higher than a buck in time? Who knows.
http://files.shareholder.com/downloads/ABEA-3S3Y3U/3311104288x0xS1144204%2D14%2D24572/1289850/filing.pdf
Gets better 7up
These are not judgments or criticism - I am getting this stuff from a distributor website.
SENSU TENS device from neurometrix
Main SENSUS page
http://www.lgmedsupply.com/sensus.html
Pricing on SENSUS page
1 device regular $890
Your price $330
2 devices regular $1,300
Your price $580
I hit on the pictures which are identical to take me to the 1 device and 2 device pages separately
1 device page
http://www.lgmedsupply.com/chpasepamasy.html
http://www.lgmedsupply.com/chpasepamasy1.html
Seems the same - I feel so well cared for. . . . . not quite 2 for the price of one
SENSUS, a TENS device by NeuroMetrix
Regular price $900
YOUR Special price to you $330 - because you're special!
Then you need the Electrode Kit @ $60 - a consumable
http://www.lgmedsupply.com/sensus.html
Go BIEL!!!!
Sensus by NeuroMetrix is a TENS device only.
Here is the ink to their 'Frequently Asked Questions' page.
http://www.sensusrx.com/pdf/sensus_clinician_faq_pn2203854_rev.c.pdf
Didn't seem to ring quite the same bell as BIEL.
would be very cool if the entire device space lit up.
Pretty sure I grabbed the right name - eNeura Therapeutics LLC - eneuera.com - from the Order release by the FDA. Deals with migraine pain.
NeuroMetrix Inc. NURO - also announces on its website that it received 510K) clearance today - deals with diabetic pain - I posed data on its trading - my bad, but it does show the space is active.
http://www.eneura.com/
sTMS Technology: How It Works
SpringTMS Total Migraine System
Turn on Power up Treat
The SpringTMS Total Migraine System uses patented single-pulse Transcranial Magnetic Stimulation (sTMS) technology.
yup and trading at 67 times average volume and up 33% - that flight has departed
Yes - that's a good link - thanks Garden.
Ha! Went back and reviewed Good Guy posts from roughly 40900 onward.
I think we've all done some good work here that we can all be proud of for contributing to. Thank goodness for the iHub forum, otherwise it would not have happened.
Good Guys may feel it's also a good tactic to send the letter to Gupta, Oz, GMA, Oprah, Helen, Letterman, Kimmel, the networks, etc., etc. Seems to me there's a groundswell opportunity here.
7up may be making the all day limo circuit of New York and LA doing all the network talk shows.
Thank you M. More than every state in the union, how about this?
If 50 people on iHub send it to 50 people in their email address book with a plea that those recipients send it on to 50 others, and so on, guess what . . . . . . .
50 iHub BIEL followers to 50 is 2,500
And they send on to 50 with the same plea is 125,000
And they send on to 50 with the same plea is 6,250,000
And they send on to 50 with the same plea is 312,500,000
4 levels, that outa do it. Called 'gettin 'er done' the old fashioned American way.
Revised draft for your review:
I am grateful for your service to the State of Mississippi and to our country – thank you. I wish to share with you an historical opportunity to make a real difference in the evolution of healthcare in our country.
You and I, and our families, and millions of Americans need your help right now because for years America has been drowning in its suffering from painkiller drug abuse. Until recently, there have been no options available and approved by the FDA other than for doctors to continue to write prescriptions, or for citizens to buy FDA approved non-prescription drug products. But now there is a U.S. company, BioElectronics Inc., that has U.S. patented pain products approved for sale in dozens of other countries, including Canada and the UK that are safe, drug-free and non-addictive. Their website is: www.bielcorp.com
The BioElectronics products, led by ActiPatch, would be timely for the VA, which is currently struggling through difficulties because its doctors continue to allegedly over-prescribe drugs to veterans, who deserve the best possible care, but with no alternatives for chronic pain. U.S. healthcare providers wrote 259 million prescriptions for opioid painkillers in 2012, enough to give a bottle of the pills to every adult in our country. But the likelihood of ending up with those pills, and the serious health risks that come with them, depends a lot on where you live, states a new report from the Federal Centers for Disease Control and Prevention.
The CDC report, published Tuesday, shows prescribing rates vary widely by state for drugs best known by brand names such as Vicodin, Percocet and OxyContin. The highest rates are in the Southeast, led by Alabama. Providers in that state wrote 143 prescriptions for every 100 residents, while providers in Hawaii, the state with the lowest rate, wrote 52 for every 100 people, nearly three times fewer. Other states with very high rates include Tennessee and West Virginia; states with low rates include California and New York.
Rates of painful illness and injuries do not vary enough from place to place to explain the differences, CDC says. Instead, high prescribing rates often reflect inappropriate uses of the drugs – which contribute to high rates of opioid painkiller overdoses, officials say. "Overdoses from opioid narcotics are a serious problem across the country and we know opioid overdoses tend to be highest where opioids get the highest use," says CDC director Tom Frieden. He says the medications "can be an important tool for doctors to use ... but they are not the answer every time someone has pain."
CDC goes on, The medications, containing narcotics such as oxycodone and hydrocodone, are intended for moderate to severe pain, the kind common after surgery, or a serious injury. But they are commonly abused. Even patients who start taking the medications for legitimate reasons can get addicted and face overdose risks. CDC says 46 people in the United States die from prescription painkiller overdoses each day. When states take action, overdose deaths can fall, according to an accompanying report from Florida. That state experienced skyrocketing drug overdose rates, linked to largely unregulated painkiller "pill mills" between 2003 and 2009, the report says. After a series of actions – including new laws to regulate pain clinics and a new prescription monitoring program – opioid overdose deaths fell 27% between 2010 and 2012. Deaths from oxycodone alone fell 52.1%. The crack-down on over-prescribing led to the shut-down of 250 pain clinics, the report says. Researchers say some of the decline in deaths might be attributed to other factors, including a new abuse-resistant oxycodone formula introduced in 2010. But they say the state's progress could be instructive for others.
I want to advise you that BioElectronics Inc. is fortunate to have the FDA now fully supportive of a new class of devices by issuing on its own initiative its 'Proposed Order' in February 2014 to create a new ‘Class II’, thereby making the devices available to all Americans by prescription. FDA requested and received public comments to its Proposed Order until May 21, 2014 and has completed its assessment of those comments, which were overwhelmingly supportive. Once FDA issues its ‘Order’ creating its Class II for BioElectronics type devices, we understand the company intends to immediately file its 510(K) application requesting that the FDA assess ActiPatch and other BioElectronics devices to allow their sale OTC - Over The Counter, in drugstores without prescription, thus making them readily available to every American man, woman and child suffering from pain.
This will dramatically reduce the many current dangers and life-threatening addictive and organ complications of chemical painkillers. Drug-free, side-effect free. Won’t you please help every one of your constituents and family members become free of harmful and addictive painkillers by becoming a positive influence in his dramatic process of change in America? I strongly believe the FDA is on the correct path of change necessary to help save and improve tens of millions of American lives and I wanted you to be aware of it. Drug-free, side-effect free. Thank you.
Hi 7up - is your letter email in draft form or has it been sent?
Paradigm shift in 40926? Excuse me please, all - although perhaps Freudian?
Absolutely right wyatt - now that the cold, hard, facts about doctors churning patients through their offices and over-prescribing pain meds is well and truly out in the public media, doctors will continue to close that door as quickly as possible because they don't want litigation for over-dosing. I would wager that insurers have already warned doctors repeatedly and for years about the negligence of over-prescribing painkillers. A good drug-free, side-effect free solution in near at hand.